FDA Approvals, New Appointments, Positive Litigation Outcomes and Partnerships - Research Report on Edwards Lifesciences, Illumina, Teva, Alere, and Dr. Reddy's

NEW YORK, September 26, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting Edwards Lifesciences Corp. (NYSE: EW), Illumina, Inc. (NASDAQ: ILMN), Teva Pharmaceutical Industries Ltd. (ADR) (NYSE: TEVA), Alere Inc. (NYSE: ALR) and Dr. Reddy's Laboratories Limited (ADR) (NYSE: RDY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Edwards Lifesciences Corp. Research Report

On September 24, 2013, The Washington Post reported that the U.S. Food and Drug Administration (FDA) approved revised labeling for Edwards Lifesciences' Sapien heart valve. As stated in the Washington Post release, the original labeling on the device instructed surgeons to thread the valve into place through a major artery that runs from the leg up to the heart, while with the new labeling, FDA allows surgeons to choose from multiple methods of implantation. The Washington Post further added that according to analysts estimates, as many as 70,000 to 100,000 patients per year could eventually receive the Sapien replacement valve. The Full Research Report on Edwards Lifesciences Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-24/EW]

--

Illumina, Inc. Research Report

On September 23, 2013, Illumina, Inc. (Illumina) announced that the Company has appointed Dr. Richard Klausner as Senior Vice President and Chief Medical Officer. According to the Company, in his role, Dr. Klausner will report to Illumina's President and CEO, Jay Flatley and will be responsible for leading the Company's strategies for advancing genomics into clinical medicine and public health. The Company also informed that Dr. Klausner will become part of Illumina's Executive Management Team, which is responsible for directing all aspects of Company strategy, planning, and operations. Illumina stated that prior to his new role, Dr. Klausner was the managing partner of the venture capital firm, The Column Group. Jay Flatley, said, "Rick's expertise in molecular biology, his experience in life sciences, and his roles in global health policy make him uniquely suited to mobilize constituents around the use of genomics within medical practice." The Full Research Report on Illumina, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-24/ILMN]

--

Teva Pharmaceutical Industries Ltd. (ADR) Research Report

On September 23, 2013, Teva Pharmaceutical Industries Ltd. (Teva) announced that the U.S. District Court for the District of New Jersey has issued a favorable drug ruling in the Company's patent infringement lawsuit against Mylan, filed in October 2010, regarding  AZILECT (rasagiline tablets) patent which covers methods of treating Parkinson's disease (PD). Teva stated that the Court upheld validity of the Company's patent. Teva expects the Court to enter Judgment that prevents Mylan from launching its generic version of Azilect until the Company's patent expires in 2017. The Full Research Report on Teva Pharmaceutical Industries Ltd. (ADR) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-24/TEVA]

--

Alere Inc. Research Report

On September 23, 2013, Alere Inc. (Alere) announced that it is partnering with "Malaria No More" on the Power of One campaign which will raise funds to deliver life-saving tests and treatment to children in Africa. The Company stated that the campaign will engage the global public and the companies to help close the malaria treatment and testing gap in Africa using the latest mobile, social, and e-commerce technologies. Alere added that every dollar donated to the campaign will provide screening and treatment for a child in Africa. The Company informed that in 2014 and 2015, it expects that more that 300 million treatments are needed to ensure that everyone with malaria has access to the life-saving tools. Avi Pelossof, Global President of Infectious Disease at Alere, said, "As the world's leading provider of rapid diagnostic tests for malaria, Alere is deeply committed to working with partners such as Malaria No More to prevent deaths from this devastating disease, one that particularly strikes young children." The Full Research Report on Alere Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-24/ALR]

--

Dr. Reddy's Laboratories Limited (ADR) Research Report

On September 17, 2013, Dr. Reddy's Laboratories Limited (ADR) (Dr. Reddy's) announced that Azactidine for Infection 100 mg/vial, which is a bioequivalent generic version of VIDAZA (azacitidine for injection), was approved by the U.S. Food and Drug Administration on September 16, 2013. Dr. Reddy's, stated that according to IMS health data, the VIDAZA brand had sales of c.$378.5 million from US for the twelve months ended July 2013. The Company also informed that it plans to launch Azactidine for Injection 100 mg/vial in the near term. The Full Research Report on Dr. Reddy's Laboratories Limited (ADR) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-24/RDY]

----    

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investors' Reports